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838LV Mass Assessed by Echocardiography and CMR,
Cardiovascular Outcomes, and Medical Practice
The authors investigated 3 important areas related to the clinical use of left ventricular mass (LVM): accuracy of assessments by
echocardiography and cardiac magnetic resonance (CMR), the ability to predict cardiovascular outcomes, and the comparative
value of different indexing methods. The recommended formula for echocardiographic estimation of LVM uses linear measure-
ments and isbasedon theassumptionof the left ventricle (LV) as aprolate ellipsoidof revolution. CMRpermits amodelingof theLV
free of cardiac geometric assumptions or acoustic window dependency, showing better accuracy and reproducibility. However,
echocardiography has lower cost, easier availability, and better tolerability. From theMEDLINE database, 26 longitudinal echocar-
diographic studiesand5CMRstudies investigatingLVMorLVhypertrophyaspredictorsofdeathormajor cardiovascularoutcomes
were identified. LVM and LV hypertrophy were reliable cardiovascular risk predictors using both modalities. However, no study
directly compared the methods for the ability to predict events, agreement in hypertrophy classification, or performance in
cardiovascular risk reclassification. Indexing LVM to body surface area was the earliest normalization process used, but it seems to
underestimate theprevalenceofhypertrophy inobeseandoverweight subjects.DividingLVMbyheight to theallometric powerof
1.7or2.7 is themostpromisingnormalizationmethod in termsofpracticalityandusefulness fromaclinical andscientific standpoint
for scalingmyocardialmass to body size. Themeasurement of LVM, calculation of LVM index, and classification for LV hypertrophy
should be standardized by scientific societies across measurement techniques and adopted by clinicians in risk stratification and
therapeutic decisionmaking. (J AmColl Cardiol Img 2012;5:837–48) © 2012 by the American College of Cardiology Foundations
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Left ventricular mass (LVM) is an independent
risk factor for prediction of cardiovascular events.
However, the best way to incorporate LVM into
clinical decision-making algorithms has not
een established (1). Even in a range usually con-
idered normal for healthy adults, LVM is posi-
ively related to systolic blood pressure, body mass
ndex, and coronary calcium score by cardiac com-
uted tomography (2,3). Elevation in myocardial
ass may not be an inevitable consequence of
ging, but better predicted by blood pressure, dia-
etes status, tobacco use, and body weight over time
4–8). Values of myocardial mass have also been
hown to be associated with previous aneurysm of
he abdominal aorta, subscapular skinfold thickness,
eft atrial size, resting heart rate, and physical
ctivity (5,7,9–11). Increase in LVM, as related to
ardiac remodeling, can be consequent to both an
daptive and a maladaptive process (12). The absence
f an identifiable, pathological turning point for car-
iac remodeling assessment from adaptive to mal-
daptive creates a challenge to the definition of normal
VM.
The distribution of LVM values is wide in a
ealthy population, with distinct patterns according
o sex and ethnicity. Moreover, absolute values of
yocardial mass are limited by not taking intoccount physiological variations related to body rize. To adjust for these particularities, indexing
VM for anthropometry allows comparisons
mong different individuals. Several methods have
een suggested for the normalization of LVM
alues—usually involving height, weight, or both.
ndexing is also important because it affects who
ill be classified as having left ventricular hypertro-
hy (LVH) (1,13–19).
Echocardiography and cardiac magnetic resonance
CMR) are the best-documented imaging modalities
sed to assess myocardial mass. In both cases,
cientific societies have elaborated guidelines dis-
ussing appropriate technical procedures, validation
spects, and clinical indications (20,21). Accurate
uantification of cardiac dimensions is crucial for
istinguishing disease states from normal variants
22). LVM is calculated using different algorithms
or each modality and gives different average values
or LVM with different degrees of accuracy (1).
Assessment of LVM in epidemiological studies has
hown prognostic value (1). The importance of LVM
nd hypertrophy for clinical purposes is best evidenced
or hypertensive populations. LVH is recognized by
urrent guidelines as target-organ damage that influ-
nces the prognosis in hypertensive populations.
owever, recommendations for incorporation of
VM or LVH into hypertension treatment algo-ithms vary in different guidelines (23–25). This partly
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839explains why on a daily basis the clinical use of LVM
measurements has not been firmly established—
although extensively used as a surrogate endpoint in
clinical trials (20,26).
In this review, we investigate 3 important points
related to clinical use of LVM measurements:
1) comparison of LVM assessment by echocardiogra-
phy and CMR; 2) outcomes prediction power of
LVM; and 3) the different normalization methods
used to index LVM. Our aim is to evaluate the
strength of the evidence regarding the use of LVM
measurements in clinical practice, as a predictor of
events and as a therapeutic target.
LVMAssessment by Echocardiography and by CMR
Echocardiography. Although LVM may be assessed
sing 2-dimensional (2D) or 3-dimensional (3D)
chocardiography, M-mode was the first noninvasive
maging technique developed and remains the recom-
ended method (20,27). Whether using M-mode,
D, or 3D measurements, LVM estimation by echo-
ardiography is based on subtraction of the left ven-
ricular (LV) cavity volume from the volume enclosed
y the correspondent epicardium to obtain the myo-
ardial volume, then multiplying by the myocardial
ensity (taken to be 1.05 g/ml) (20). At the present
ime, the lack of long-term follow-up information
sing 2D or 3D echocardiography estimations of
VM as event predictors limits further discussion in
his review.
In patients without major cardiac geometry dis-
ortions, the American Society of Echocardiogra-
hy (ASE) recommends a formula to estimate
VM from linear dimensions based on the assump-
ion of the LV as a prolate ellipsoid of revolution
Fig. 1). Linear measurements of interventricular
eptum wall thickness (IVST), as well as left ven-
ricular internal diameter (LVID) and posterior wall
hickness (PWT), should be done from the paraster-
al acoustic window in end-diastole at the level of the
V minor axis (mitral valve leaflet tips) using 2D-
argeted M-mode or directly from 2D images (20).
lthough wall dimensions are used to assess LVM by
chocardiography, regional increase in wall thickness
een in hypertrophic cardiomyopathy is a specific
isease and will not be addressed in this review.
The first challenge to echocardiographic assessment
f LVM is the correct identification of interfaces
etween the cardiac blood pool and the endocardium,
s well as between the epicardium and pericardium.
he correct M-mode reference beam orientation per-
endicular to the septum can also be challenging. Poorcoustic windows and operator experience are also
ajor concerns for echocardiography measurements.
he LVM algorithm is performed cubing values of
he primary linear measurements, which therefore
agnifies measurement errors.
The need to calculate myocardial volume cubing
inear dimensions—due to the geometric assump-
ion of the prolate ellipsoid—is the major limitation
or LVM estimated by M-mode echocardiography
s related to accuracy and reproducibility (28–31).
RESERVE (Prospective Randomized Enalapril
tudy Evaluating Regression of Ventricular En-
argement) assessed intrapatient reliability (inter-
can reproducibility) of echocardiographic LVM
easurements, repeating echocardiograms in 183
ypertensive subjects with LVH. The in-
raclass correlation coefficient (ICC) for
he linear measurements was 0.87 for
VID, 0.85 for IVST, and 0.83 for PWT
32). Bottini et al. (33) also assessed inter-
can reproducibility, repeating echocardio-
rams in 22 hypertensive subjects, and
eported an average mean difference of
.3 g between exams, with 95% limits of
greement from 96.3 g to 96.9 g. The
ame authors also had 2 readers indepen-
ently assessing 24 echocardiography im-
ges, finding mean differences (95% limits
f agreement) of 1.83 g (48.8, 52.5)
33). Intrareader reproducibility for LVM
y echocardiography was evaluated in 735
hildren of HIV-infected mothers in the
rospective P(2)C(2) HIV study (34).
chocardiograms were analyzed in 10
linical sites and then reassessed at a cen-
ral facility. The internal LVID showed
he highest agreement (ICC  0.97), but
lower correlation was found for PWT
(ICC  0.65) and IVST (ICC  0.50) (34). Also
or intrareader reproducibility, 21 subjects were
ssessed by Missouris et al. (29), showing a mean
oefficient of variation (95% confidence interval
CI]) of 6.1% (3.9 to 8.3). Using 20 hypertensive
ale subjects, Spratt et al. (35) investigated echo-
ardiography inter-reader reproducibility and found
ean differences (95% limits of agreement) for
VM/body surface area (BSA) between 4.5 g/m2
(24.9, 33.9) and 6.4 g/m2 (23.0, 35.8) for
harmonic imaging (HI) and fundamental imaging
(FI), respectively.
The ASE-recommended algorithm is based on the
formula first described by Devereux et al. in 1977,
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840to improve definition of pericardial and endocardial
borders, HI replaced FI in clinical practice. In the
past, FI was limited to a fixed frequency for output
and receiving (usually 2.5 mHz), but the advent of
HI allowed the emission of low-frequency ultrasound
for good penetration and the reception of signal 2
octaves higher (38). When assessed by M-mode
echocardiography, HI shows higher values for LVM
compared with FI, but seems to correlate better to
CMR measures (30,35,38,39).
Cardiac magnetic resonance. LVM evaluation by
MR permits a 3D high-resolution modeling of the LV
ree of cardiac geometric assumptions, contrast infusion,
coustic window dependency, or ionizing radiation. Both
hort-axis and long-axis techniques are highly accurate
or quantification of LVM (40). The best-documented
echnique, however, uses a set of contiguous short-axis
lices covering the entire LV from the atrioventricular
ing down to the apex, acquired from a cine sequence. A
ombination of body matrix/torso radio frequency coils is
sed for the acquisition, using a 2D cardiac-gated pulse
Figure 1. Principles for the Assessment of LVM by Echocardiogr
(A) A prolate ellipsoid of revolution, or prolate spheroid, is a 3-dim
The American Society of Echocardiography (ASE)-recommended for
tion shape, with minor radii that are half the major radius. (B) Sche
of LVM by echocardiography (parasternal view), according to the A
2  left ventricular internal dimension (LVID); 3  posterior wall thick
steps for the estimation of left ventricular myocardial volume, as in
then calculated by multiplying the myocardial volume by the speci
ventricular volume (VolumeT). (D) Calculation for the left ventricular
lar myocardial volume (VolumeM). (F) The current ASE-recommende
cepts, but includes correction factors derived from regression analyequence. Ideally, images are acquired at resting lung (olume. Myocardial volume is the area occupied be-
ween the endocardial and epicardial border multi-
lied by the interslice distance. By convention, LVM
s measured at end-diastole. Similar to echocardiog-
aphy, LVM is the product of this volume and the
ensity of the myocardium (Fig. 2).
Early controversies were related to contour
ifferences in LV quantification by CMR, with
mall studies favoring inclusion of papillary mus-
les in the calculation of myocardial mass (41–43).
n fact, the measurement technique significantly
nfluences the estimation of LVM (44). However,
ESA (Multi-Ethnic Study of Atherosclerosis) en-
olled the largest population with CMR assessment
nd showed better reproducibility when papillary
uscles were excluded (45).
Technical developments in CMR image acquisi-
ion and post-processing influence LVM measure-
ents. Black-blood techniques were previously used
o assess LVM by CMR, moving to cine bright-blood
echniques. More recently, steady-state free precession
y, as Recommended by the ASE
nal ﬁgure formed by revolving an ellipse about its major axes.
a assumes that the left ventricle has a prolate ellipsoid of revolu-
ic representation of the linear measurements for the assessment
ecommendations. 1  interventricular septum thickness (IVST);
(PWT). (C to E) Images refer to a schematic representation of the
y proposed by Devereux et al. (28). Left ventricular mass (LVM) is
ravity of myocardium (1.05 g). (C) Calculation for the total left
ernal cavity volume (VolumeC). (E) Calculation for the left ventricu-
rmula for the assessment of LVM. It is based on the initial con-
20,35).aph
ensio
mul
mat
SE r
ness
itiall
ﬁc g
int
d foSSFP) has replaced fast gradient-echo (GRE) se-
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841quences as the preferable CMR cine bright-blood
technique. Compared with GRE techniques, SSFP
sequences have substantially higher signal-to-noise
and contrast-to-noise ratios and shorter acquisition
times (46). SSFP sequences improve homogeneity of
the blood pool signal and definition of the endocardial
border throughout the cardiac cycle, improving the
performance of automatic and manual delineation of
contours for assessment of LVM (47). Studies com-
paring SSFP and GRE for calculation of LVM
demonstrated a lower mass measured by the SSFP
sequence, but both methods demonstrated good re-
producibility (47,48).
In healthy participants, LVM assessed by CMR
shows susceptibility to interobserver variation (49).
Using 9 normal young volunteers, Missouris et al.
(29) found CMR intrareader reproducibility be-
tween LVM estimations of 0.5% with 95% limits of
agreement of 11%. Bottini et al (33). assessed
intrareader reproducibility in a population of 34
hypertensive subjects, finding mean differences
(95% limits of agreement) of 0.32 g (20.1, 21.7).
Gandy et al. (50) showed that intrareader reproduc-
ibility of LVM measurements by CMR are depen-
dent upon the clinical cardiac condition under
investigation, with intraobserver coefficients of re-
Figure 2. Images From CMR of 2 Patients With Chagas Cardiom
Case 1 has preserved cardiac geometry, but case 2 shows left ventr
resonance (CMR) does not require cardiac geometry assumptions, a
tesy of Dr. Gustavo Volpe.) (A and C) CMR-derived images represen
LVM. The anterior septal wall (ASW) corresponds to the interventric
to the left ventricular internal dimension; and the posterior lateral w
the ASE-recommended formula was used to calculate LVM (see Fig
using contiguous short-axis slices covering the entire left ventricle
is displayed at the bottom. Abbreviations as in Figure 1.peatability of 4.6 g for healthy volunteers, 6.7 g forpost-myocardial infarct patients, 8.3 g in patients
with congestive heart failure, and 9.8 g in patients
with LVH. Moreover, Bellenger et al. (51) investi-
gated 15 healthy adult volunteers and 15 patients
with chronic stable heart failure that underwent 2
CMR scans 7 days apart, with correlation coeffi-
cient for the assessment of LVM of 0.99 and
interscan average difference (95% limits of agree-
ment) of 0.7 g (6.3, 9.7) and 0.7 g (11.9, 13.3)
for normal and heart failure patients, respectively.
In fact, among the evaluations of LV volume, mass,
and function by CMR, LVM appears to be the least
reproducible and most variable parameter (44). This is
because LVM is derived from the difference of 2
volumes (total LV volume and end-diastolic volume).
Although gradually less significant over time, addi-
tional important limitations for wide clinical use of
CMR include the following: elevated operational cost,
time to acquire and analyze cine data, breath-hold
dependency, hazards associated with ferromagnetic
metal devices, and issues related to claustrophobia in
susceptible patients.
Echocardiography versus CMR. Although CMR and
echocardiographic LVM measurements show high
correlation, absolute values of LVM differ between
these techniques (Fig. 2) (29,30). The difference
athy
ar remodeling. The usual assessment of LVM by cardiac magnetic
posed to linear measurements used in echocardiography. (Cour-
usual echocardiography views for linear measurements assessing
septal thickness; the end-diastolic dimension (EDD) corresponds
(PLW) corresponds to the posterior wall thickness. At the bottom,
or a full description). (B and D) Usual CMR assessment for LVM,
the atrioventricular ring to the apex (1 to 9). The estimated LVMyop
icul
s op
ting
ular
all
. 1 f
fromamong estimates by echocardiography and CMR
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842indicates that the 2 methods cannot be used inter-
changeably in the assessment of LVM (33). Echo-
cardiography is less expensive and has superior
versatility, acceptability, and availability compared
with CMR. These are practical issues that support
clinical use of LVM assessed by echocardiography
as an outcome predictor, as recommended by the
most recent American Heart Association statement
on cardiovascular risk assessment (52).
However, LVM determined by CMR is more
accurate and precise than that provided by M-mode
echocardiography (33). Interstudy reproducibility of
CMR-derived parameters for LVM is also superior to
2D echocardiography for normal, dilated, and hyper-
trophic hearts (53). In fact, research studies using this
method require substantially smaller sample sizes to
assess outcome measures (51,53). The variability of
echocardiography for evaluation of serial LVM
changes has generated concerns (54). The previously
reported probability of a true biological change in
observed/predicted LVM over time was maximized
for a single-reader difference 22% (55). Three-
dimensional echocardiography improves accuracy and
reproducibility compared with CMR, but is strongly
dependent on equipment and technical conditions
such as acoustic window quality (56–61).
LVM as a Predictor of Events
Longitudinal studies present in the MEDLINE da-
tabase that investigated LVM, LVM index (LVMi),
or LVH assessed by echocardiography or CMR as
predictors of death or major cardiovascular outcomes
were included in this analysis. The following criteria
were applied to select articles: 1) echocardiographic
studies using the ASE recommendations for chamber
quantifications by M-mode technique (20,37);
2) survival analysis studies reporting hazard ratios and
95% CI; and 3) reports from multivariate analyses
adjusted for at least 2 other traditional risk factors. In
each study, analysis adjusted for the highest number of
traditional cardiovascular risk factors was included.
Analyses using covariates derived from other graphic/
imaging diagnostic methods such as electrocardiogra-
phy, ejection fraction, and LV volumes were excluded.
Analyses that included pooled LVM data were ex-
cluded unless a classification of hypertrophy was
clearly defined. For each study, we describe the mean
follow-up time.
We included 26 longitudinal echocardiographic
studies (Online Table 1) in our review. From those,
11 reported non-normalized LVM or LVMi as
predictors of clinical outcomes (Online Fig. 1); 12reported LVH (Online Fig. 2); and 8 reported serial
changes in LVM or LVH status over time (Online
Fig. 3). We included 5 studies for LVM assessed by
CMR (Online Table 2). All CMR studies reported
LVMi as outcome predictor; 2 also reported non-
normalized LVM; and 1 additionally evaluated
LVH. In the echocardiography group, a remarkable
predominance of studies was oriented toward inves-
tigating hypertensive populations. For the CMR
group, 4 of the 5 studies were based on participants
from MESA, a population free from known cardio-
vascular disease at inclusion, using different out-
comes and diverse methods for indexing LVM.
Online Tables 1 and 2 also show the vast number of
different LVH definitions used in these studies.
In Online Figure 4, the hazard ratios and 95% CI
for the CMR group of studies are displayed accord-
ing to the method used to index LVM, hypertrophy
classification, and predicted outcomes. The 5 lon-
gitudinal CMR studies provide hazard ratios from
33 models. A direct comparison of events predictors
is difficult due to the use of different clinical
endpoints. Regardless of which method is used for
normalization of LVM, however, most models
demonstrated significant ability to predict events.
For LVMi, the overall hazard ratio ranged from 1.0
(95% CI: 0.9 to 1.1) for prediction of coronary heart
disease (62) to 2.2 (95% CI: 1.4 to 3.4) for predic-
tion of a combined endpoint, including coronary
heart disease or stroke (18).
Hazard ratios for the ability to predict events
reported for LVM and LVMi in the echocardiog-
raphy studies are shown in Online Figure 1, along
with the mode of indexing and endpoint defini-
tions. The 11 studies reported hazard ratios from 33
models. The hazard ratios ranged from 1.0 (95%
CI: 0.99 to 1.02) for LVM indexed by BSA among
subjects with diabetes—predicting a combined end-
point of cardiovascular death, ischemic heart dis-
ease, heart failure, end-stage renal disease, periph-
eral arterial disease, and stroke (63)—to 2.8 (95%
CI: 1.6 to 4.7) for LVM predicting all-cause deaths
among patients with heart failure (64).
The ability to predict events according to myo-
cardial hypertrophy status by echocardiography is
displayed in Online Figure 2. From the 10 included
studies, 30 hazard ratios were reported. The hazard
ratios ranged from 1.01 (95% CI: 1.0 to 1.02) for
inappropriate LVM (28% of excess, obtained by
dividing LVM by predicted values based on a
reference sample), predicting a composite endpoint
(65) (see “composite 1” in the Online Fig. 2 legend
for a full description) to 4.14 (95% CI: 1.8 to 9.7)
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843for LVH in patients without coronary artery dis-
ease, predicting all-cause mortality (66). Few stud-
ies are comparable, however, due to methodological
differences. The majority of the studies report
significant power to predict events for LVM, for
LVMi, and for hypertrophy.
We assessed the ability to predict cardiovascular
events by changes in LVMi or LVH classification
over time using only echocardiography. Hazard
ratios for serial changes in LVM or LVH status are
displayed in Online Figure 3, with predicted out-
come and mode of normalization. A total of 23
hazard ratios were reported in the 8 studies provid-
ing information on LVM and LVH status changes.
In summary, the risk gradually increased according
to LVM at baseline, with an increasing LVM or
hypertrophy grading. When LV mass regressed
after treatment, the hazard ratio was favorable,
predicting an extensive composite endpoint (hazard
ratio: 0.18, 95% CI: 0.05 to 0.7) (67) (see “com-
posite 5” in the Online Fig. 3 legend for a full
description). A maintained LVH status, however,
significantly predicted a different composite end-
point (hazard ratio: 3.52, 95% CI: 2.5 to 4.6) (68)
(see “composite 2” in the Online Fig. 3 legend for a
full description).
Indexing Process
During the review process, we assessed several
criteria used to normalize LVM. Online Figures 1,
3, and 4 display the wide variety of methods used to
calculate LVMi. Heart size scales with the size of
the body (22). Several different methods have been
suggested for indexing LVM to anthropometric
measures, usually based on height and/or weight,
but the optimal way to normalize myocardial mass
has not been established (20). Alternatively, proce-
dures where measured LVM is indexed by dividing
by expected LVM (based on a reference population
free of major cardiovascular risk factors) have also
been proposed, adding complexity to the calculation
of LVMi. The most commonly used formula for
computing BSA—the Dubois and Dubois regres-
sion (BSA  0.007184  weight [Kg]0.425 
eight [cm]0.725)—is based on an assessment of 9
adaveric subjects reported in a 1916 publication,
nd its validity has been questioned (18,22,69).
Indexing LVM to BSA was the first normaliza-
ion process used, but it seems to underestimate the
revalence of LVH in obese as well as in overweight
ypertensive patients (17). Conversely, the preva-ence of hypertrophy is higher in obese individualsor height-based indices that do not account for
eight in overweight individuals (18). The purpose
f indexing LVM for height with an allometric
xponent is to attempt to approximate lean body
ass and to possibly adjust for the impact of growth
uring childhood (70). Compared with LVM/BSA
nd LVM/height, indexation of LVM by height2.7
appears to adjust better for the relations between
height and LVM in hypertensive, obese individuals
and to reduce the variability among normal subjects,
providing a more sensitive cutoff for LVH (70,71).
Comparing LVM indexed by BSA and height2.7,
LVM/height2.7 has a better performance as a
unique criteria to detect LVH prevalence in obese
subjects (72). Also, in acromegaly, LVM indexed
for height2.7 appears to be the most appropriate
method to identify LVH—particularly in patients
who are also overweight (73).
Using a population of hypertensive subjects with
low prevalence of obesity, de Simone et al. (74)
(Online Table 1) compared indexing methods for
LVM assessed by echocardiography as predictors of
cardiovascular events. After adjustment for age and
sex, indexing by height, height2.7, or height2.13
performed as well as BSA as outcome predictors
(Online Fig. 1). de Simone also investigated Amer-
ican Indians free of cardiovascular disease, but with
a high prevalence of obesity (Online Table 1) (75).
Adjusted for age and sex, the presence of LVH
identified by LVM normalized by height2.7 and
eight2.13 was associated with a higher proportion
f outcomes than was LVH detected using LVM
ormalized by BSA (Online Fig. 1). In a cohort of
atients undergoing dialysis (Online Table 1), more
ubjects were classified with LVH by LVM/
eight2.7 compared with LVM/BSA (76). In this
opulation, LVH classified either by normalization
o BSA or height2.7 predicted total and cardiovas-
ular mortality. However, LVM/height2.7 demon-
trated better predictive ability compared with
VM/BSA (Online Fig. 1).
For LVM assessed by CMR, 2 studies used
ESA (15) participants to compare indexing
ethods in their ability to predict clinical events
Online Table 2) (18,19). Chirinos et al. (19)
nitially included MESA CMR data and echocar-
iography data from the Asklepios Study (77) to
ompare LVM indexed by BSA, height, height1.7,
or height2.7 in relation to the LVH classification.
he authors conclude that indexation by height1.7
would provide the best description of the relation-
ship between LVM and body size in both echocar-
diography and CMR assessments. However, only
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844the white and Chinese participants from MESA
and white European subjects from the Asklepios
Study were included in the analyses for the allomet-
ric exponent comparisons. In this study, survival
analysis to establish the best indexation procedure
was shown only for the MESA population. LVH
defined by LVM/height1.7 was reported to be re-
lated to all cardiovascular events, to hard cardiovas-
cular events, and to all-cause mortality. Normaliza-
tion by either height2.7 or BSA, however, failed to
predict all-cause mortality (Fig. 1) (19). Also using
MESA participants, Brumback et al. (18) investi-
gated LVM indexed by BSA, height2, height2.7,
nd 2 other allometric indices (percent-predicted
V mass based on height and sex; and percent-
redicted LVM based on height, weight, and sex).
he study found a higher prevalence of hypertrophy
or indices that do not account for weight, but no
ignificant difference was detected between indices
or the outcomes prediction ability (18).
Gaps in Knowledge
An increase in LVM is the most important com-
ponent of cardiac remodeling, resulting from an
incompletely understood balance between cardiac
stressors and compensatory mechanisms (12,28,78).
However, the exact point when the increase of
myocardial mass turns from an adaptive process to
pathology is unknown. Obesity may be related to
both adaptive and pathological increases in LVM.
Future studies should address whether indexing
methods can not only adjust for body size, but also
account for adaptive changes in the obese and
whether they influence clinical decision making.
The appropriate consideration of body size in the
evaluation of cardiovascular structure affects recogni-
tion and treatment of cardiovascular disease states in
pediatric and adult patients (22). The best approach
seems to be normalization of LVM by height to some
allometric power, specifying cutoff values of normality
according to sex and ethnicity. When considering the
definition of the appropriate height allometric expo-
nent, the current literature still has important gaps in
knowledge. Although height1.7 seems to be promising
o establish the best description for the relation be-
ween myocardial mass and body size, there are still
trong limitations related to the cutoff definitions and
o the limited longitudinal data available—especially
or echocardiographic assessment of LVM. In this
egard, most of the longitudinal scientific evidence is
till related to normalization by height2.7.A reduction in intervertebral disk diameter occurs
with aging, possibly accounting for artifactual individ-
ual changes over time in indexed parameters. Cumu-
lative height loss from age 30 to 70 years may decrease
approximately 3 cm of the original height for men and
5 cm for women (79). It affects the calculation of BSA,
but should have higher impact on methods adjusted
uniquely to height to an allometric power. However,
the implications on LVMi of height changes related
to aging are still unknown.
The majority of longitudinal studies assessing
CMR-derived LVM predicting outcomes are from
the MESA study (Online Table 2). Although
addressing a large multiethnic population, the
MESA results should be tested in other populations
to assess how universal are these findings. There are
also unclear aspects related to the assessment of
LVM by CMR regarding the LV basal slices.
Including or not including a more basal slice can be
a major source of variability in the final LVM
calculation, but this issue is not properly addressed
in the literature. On the basis of the experience with
the MESA study, a slice-by-slice analysis consider-
ing base when myocardium is present in more than
50% of the short-axis circumference appears to be
appropriate. MESA also set the normality range for
functional CMR and showed clinical event predic-
tion for LVM assessed by resonance (15,19,62).
However, these assessments were done with the
GRE technique. The fact that GRE has been
replaced by SSFP urges the necessity of new stan-
dard cutoff values for normality that account for
technical differences.
Although CMR showed better performance than
echocardiography for accuracy and precision in LVM
evaluation (33), no direct comparison of the 2 meth-
ods has been performed for the ability to predict
clinical events, the agreement for hypertrophy classi-
fication, or the cardiovascular risk reclassification. It is
unknown how concordant CMR and echocardiography
are regarding hypertrophy classification—especially
when different indexing methods are considered.
Additionally, there is a lack of knowledge regarding
the risk reclassification for LVM when compared
with traditional risk assessments (52,80).
Recommendations and Future Perspectives
We showed that LVM assessed by echocardiogra-
phy has a good event prediction power, but has
major limitations related to the need for cardiac
geometric assumptions. Therefore, the ASE-
recommended formula should be reported in all
L
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845echocardiograms performed in patients without
major LV remodeling. To improve accuracy and
reproducibility across laboratories, strict quality
control recommendations should be enforced. In
this regard, the Intersocietal Accreditation Com-
mission for Echocardiography requires the mea-
surement of IVST, PWT, and LVID by 2D or
M-mode imaging, but has no special recommenda-
tion for LVM assessment (81). Laboratories should
have technicians regularly perform intraobserver
and interobserver reliability assessments to improve
measurement accuracy.
The currently preferable method for LVM assess-
ment by CMR is based in the scientific evidence
collected by the MESA study, leading to the short-
axis evaluation, with exclusion of papillary muscle. In
addition, to include basal slides when myocardium is
present in more than 50% of the short-axis circum-
ference would be consistent with the MESA protocol.
The Intersocietal Accreditation Commission for
Magnetic Resonance has not made specific recom-
mendations on LVM as criteria for quality control
(82). Recommendations on standard reports and qual-
ity assessment should be consented by scientific
societies.
For echocardiography, indexing LVM by height to
the allometric power of 1.7 or 2.7 has shown the best
relation to body size and events prediction. However,
normal reference values have not been firmly estab-
lished. Cutoff values endorsed by the ASE are based
on FI technique and thus may not be applicable to the
HI era. Values are not standardized for different
ethnicities. For CMR, most of the longitudinal scien-
tific evidence is based only on the MESA cohort of
participants using GRE sequences. Standard recom-
mendations for indexing and cut-points for hypertro-
phy across imaging modalities are needed to match
current technologies used in daily practice.
The National Heart, Lung, and Blood Institute’s
Fourth Report on the Diagnosis, Evaluation, and
Treatment of High Blood Pressure in Children and
Adolescents (24) recognizes LVH as the most
prominent clinical evidence of target-organ damage
caused by hypertension in children and adolescents.
The guidelines incorporate LVM measurement in
the evaluation algorithm, recommending intensifi-
cation of antihypertensive management if there is
presence of LVH. However, the role of periodic
echocardiographic determination of LVMi is re-
stricted to patients who have established LVH (24).
The Eighth Report of the Joint National Commit-
tee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC-8) is Mexpected to be released in 2012 (83). The previous
edition also lists LVH as target-organ damage for
the heart and an independent risk factor. Aggressive
blood pressure management is described as a strat-
egy for LVH regression. However, echocardiogra-
phy is not included among the routine or even in
the optional tests and procedures (25). The Euro-
pean Society of Cardiology Guidelines for manage-
ment of arterial hypertension uses LVH as criteria
of subclinical organ damage influencing prognosis
(23). In this context, echocardiography is recom-
mended during diagnostic evaluation for more pre-
cise stratification of overall risk and for checking the
status of organ damage during follow-up visits. In a
therapeutic view, effects of different drugs on LVM
and LVH are discussed. However, LVMi variation
is not stated among therapeutic goals (23).
The way clinicians use LVM in their practice
may not reflect the scientific recommendations
from medical societies. An important issue related
to LVM is its restricted clinical use in daily practice
in contrast to the regular use of measurements of
cardiac systolic function (20). In a multicenter
survey performed in Italy, hypertension accounted
for approximately 30% of echocardiographic exam-
inations in outpatient hospitals or academic echo-
cardiography labs (84). However, a large majority of
echocardiographic examinations routinely per-
formed on hypertensive patients did not report data
on LVM, and if reported, the results were usually
not indexed to anthropometric variables (84,85).
Conclusions
In the assessment of LVM, no superiority between
echocardiography and CMR may be stated at this
time, due to the absence of studies directly comparing
the methods. Assessed by both echocardiography and
CMR, LVM, and LVH are reliable cardiovascular
event predictors. LVM assessed by echocardiography
is more practical on a clinical basis. CMR would be
preferable for research and specific clinical conditions
requiring higher accuracy and reproducibility. Divid-
ing LVM by height to some allometric power is the
most promising indexing method for scaling myocar-
dial mass to body size. The measurement of LVM and
a definition of LVH based on outcomes should be
agreed upon by scientific societies considering all
available techniques.
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